Insulin metabolism in human adipocytes from subcutaneous and visceral depots

Biochemical and Biophysical Research Communications

Volumn 402, Issue 4, 2010, Pages 762-766

  Fawcett, Janet ^a   Sang, Hairong ^a   Permana, Paska A ^a,b   Levy, Jennifer L ^a   Duckworth, William C ^a,b,c  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Human adipose tissue; Insulin degradation; Insulin degrading enzyme; Subcutaneous; Visceral

Indexed keywords

BACITRACIN; CHLOROQUINE; INSULIN; INSULINASE; LEUPEPTIN; PEPSTATIN;

ADIPOCYTE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN DEGRADATION; INTRAABDOMINAL FAT; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; SUBCUTANEOUS FAT;

ABDOMINAL FAT; ADIPOCYTES; ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN B; CATHEPSIN D; FEMALE; HUMANS; INSULIN; INSULYSIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SUBCUTANEOUS TISSUE;

EID: 78649448389     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.104     Document Type: Article

References (37)

1. Hamdy O., Porramatikul S., Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr. Diabetes Rev. 2006, 2:367-373.
2. Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J. Diabetes Complications 2000, 14:154-174.
3. Rader D.J. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am. J. Med. 2007, 120:S12-S18.
4. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 2000, 21:697-738.
5. Bergman R.N., Kim S.P., Hsu I.R., Catalano K.J., Chiu J.D., Kabir M., Richey J.M., Ader M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med. 2007, 120:S3-S8. (discussion S29-S32).
6. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases,. Eur. Heart J. 2008, 29:2959-2971.
7. Ibrahim M.M. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 2009, 11:11-18.
8. Lafontan M., Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights?. Trends Pharmacol. Sci. 2003, 24:276-283.
9. Zierath J.R., Livingston J.N., Thorne A., Bolinder J., Reynisdottir S., Lonnqvist F., Arner P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 1998, 41:1343-1354.
10. Bolinder J., Kager L., Ostman J., Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983, 32:117-123.
11. Lundgren M., Burén J., Myrnäs T., Ruge T., Eriksson J. Glucocorticoid-induced insulin resistance in visceral but not subcutaneous human adipocytes. Diabetes 2003, 52:A84. [Abs].
12. Boivin A., Brochu G., Marceau S., Marceau P., Hould F.S., Tchernof A. Regional differences in adipose tissue metabolism in obese men. Metabolism 2007, 56:533-540.
13. Livingston J.N., Lerea K.M., Bolinder J., Kager L., Backman L., Arner P. Binding and molecular weight properties of the insulin receptor from omental and subcutaneous adipocytes in human obesity. Diabetologia 1984, 27:447-453.
14. Perrini S., Laviola L., Belsanti G., Cignarelli M., Cuscito M., Neri V., Cignarelli M., Giorgino R., Giorgino F. Insulin signaling in human adipose tissue depots in vivo. Diabetes 2003, 52:A309. (Abs).
15. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
16. Martinez E. Fat accumulation and HIV-1 protease inhibitors. Lancet 1998, 352:1392.
17. Murata H., Hruz P.W., Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 2000, 275:20251-20254.
18. van der Valk M., Bisschop P.H., Romijn J.A., Ackermans M.T., Lange J.M., Endert E., Reiss P., Sauerwein H.P. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001, 15:2093-2100.
19. Kino T., Chrousos G.P. AIDS-related insulin resistance and lipodystrophy syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2003, 3:111-117.
20. Mallon P.W., Wand H., Law M., Miller J., Cooper D.A., Carr A. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J. Acquir. Immune Defic. Syndr. 2005, 38:156-162.
21. Dowell P., Flexner C., Kwiterovich P.O., Lane M.D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem. 2000, 275:41325-41332.
22. Zhang B., Macnaul K., Szalkowski C., Li Z., Berger J., Moller D.E. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin. Endocrinol. Metab. 1999, 84:4274-4277.
23. Ranganathan S., Kern P.A. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J. Endocrinol. 2002, 172:155-162.
24. Rudich A., Vanounou S., Riesenberg K., Porat M., Tirosh A., Harman-Boehm I., Greenberg A.S., Schlaeffer F., Bashan N. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001, 50:1425-1431.
25. Martinez E., Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 1998, 352:821-822.
26. Hamel F.G., Fawcett J., Tsui B.T., Bennett R.G., Duckworth W.C. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes. Metab. 2006, 8:661-668.
27. Duckworth W.C., Bennett R.G., Hamel F.G. Insulin degradation: progress and potential. Endocr. Rev. 1998, 19:608-624.
28. Erdmann J., Mayr M., Oppel U., Sypchenko O., Wagenpfeil S., Schusdziarra V. Weight-dependent differential contribution of insulin secretion and clearance to hyperinsulinemia of obesity. Regul. Pept. 2009, 152:1-7.
29. Duckworth W.C., Hamel F.G., Peavy D.E. Two pathways for insulin metabolism in adipocytes. Biochim. Biophys. Acta 1997, 1358:163-171.
30. Permana P.A., Zhang W., Wabitsch M., Fischer-Posovszky P., Duckworth W.C., Reaven P.D. Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1076-E1084.
31. Bashan N., Dorfman K., Tarnovscki T., Harman-Boehm I., Liberty I.F., Bluher M., Ovadia S., Maymon-Zilberstein T., Potashnik R., Stumvoll M., Avinoach E., Rudich A. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. Endocrinology 2007, 148:2955-2962.
32. Fawcett J., Hamel F.G., Duckworth W.C. Characterization of the inhibition of protein degradation by insulin in L6 cells. Arch. Biochem. Biophys. 2001, 385:357-363.
33. Kupfer S.R., Wilson E.M., French F.S. Androgen and glucocorticoid receptors interact with insulin degrading enzyme. J. Biol. Chem. 1994, 269:20622-20628.
34. Duckworth W.C., Bennett R.G., Hamel F.G. A direct inhibitory effect of insulin on a cytosolic proteolytic complex containing insulin-degrading enzyme and multicatalytic proteinase. J. Biol. Chem. 1994, 269:24575-24580.
35. Bennett R.G., Hamel F.G., Duckworth W.C. Insulin inhibits the ubiquitin-dependent degrading activity of the 26S proteasome. Endocrinology 2000, 141:2508-2517.
36. Hamel F.G., Bennett R.G., Upward J.L., Duckworth W.C. Insulin inhibits peroxisomal fatty acid oxidation in isolated rat hepatocytes. Endocrinology 2001, 142:2702-2706.
37. Authier F., Metioui M., Fabrega S., Kouach M., Briand G. Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. J. Biol. Chem. 2002, 277:9437-9446.